Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 1

Episode 1:
Opening & Keynote Speech: First-line treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC)
Enrique Grande, MD, MSc, PhD

The therapeutic landscape of unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) has undergone a significant transformation in recent years with the addition of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and novel antibody-drug conjugates (ADCs) to the treatment armamentarium. In real-world practice, factors such as drug accessibility, clinical characteristics, adverse events, and patient preferences greatly influence treatment decisions across diverse geographical regions. Therefore, it is crucial to develop an optimal treatment strategy tailored to the individual needs of patients in the first-line (1L) setting. In this educational program on ‘Best Practice Exchange in Clinical Case Scenarios’, experts in the field will discuss the latest evidence supporting the use of these therapies in clinical practice, including patient selection criteria for platinum eligibility and ineligibility, optimal 1L treatment strategies and immunotherapy maintenance approaches, considerations for treatment sequencing, and management of treatment-related adverse events (TRAEs). An improved understanding of the role and application of individual 1L treatment strategies in routine patient care will facilitate optimal management for patients with urothelial cancer.